EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case report: Personalized, response-adapted neoadjuvant alectinib achieves durable remission in stage IIIB ALK-rearranged lung cancer

Hui Shen, Sishi Huang, Jianbin Zhang

Frontiers in Pharmacology · 19.05.2026 · 17

DOI: 10.3389/fphar.2026.1758062 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.05.2026. Verfasst von Hui Shen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejia…. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alectinib, a second-generation ALK inhibitor, is established as a first-line treatment for advanced ALK-positive NSCLC and as adjuvant therapy following resection for early-stage disease. However, its role as a neoadjuvant therapy remains under investigation. Case presentation We report a 57-year-old never-smoking woman diagnosed with stage IIIB (cT4N2M0) ALK-rearranged lung adenocarcinoma. After the initial multidisciplinary team (MDT) convening, a consensus was reached to initiate neoadjuvant alectinib (600 mg twice daily), with the first response evaluation scheduled at 4 weeks. The first restaging computed tomography (CT) demonstrated a significant partial response (PR), characterized by a 76% reduction in the primary tumor diameter and a 50% reduction in the short axis of the station 7 lymph node. In light of this robust response which already met surgical criteria, the MDT decided to proceed with a second 4-week consolidation cycle to maximize the pathological response prior to surgery. Following the second cycle, subsequent imaging confirmed further tumor regression. The patient then underwent successful R0 resection, with pathology confirming a major pathological response (MPR). Adjuvant alectinib was resumed on postoperative day 2. At the last follow-up (33 months post-surgery), the patient remains disease-free with no clinically significant treatment-related adverse events.

Conclusion

This case illustrates the successful personalization of neoadjuvant alectinib by employing an imaging response-adapted strategy. This strategy utilized dynamic imaging assessments to guide the scheduling of the surgical procedure, culminating in a deep pathological response and prolonged disease-free survival, thereby offering a refined perioperative paradigm for ALK-rearranged NSCLC.

Schlagwörter

Stichwörter der Autor:innen

alectinibcase reportneoadjuvant therapynon-small cell lung cancerresponse-adapted strategy

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, China.
  • Department of Thoracic Surgery, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China.

Zitieren

APA

Shen, H., Huang, S., & Zhang, J. (2026). Case report: Personalized, response-adapted neoadjuvant alectinib achieves durable remission in stage IIIB ALK-rearranged lung cancer. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1758062

Vancouver

Shen H, Huang S, Zhang J. Case report: Personalized, response-adapted neoadjuvant alectinib achieves durable remission in stage IIIB ALK-rearranged lung cancer. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1758062

BibTeX
@article{Shen2026,
  author = {Shen, Hui and Huang, Sishi and Zhang, Jianbin},
  title = {Case report: Personalized, response-adapted neoadjuvant alectinib achieves durable remission in stage IIIB ALK-rearranged lung cancer},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1758062}
}
Kostenlos starten →